Ticker Details
Protalix BioTherapeutics, Inc. Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx.
IPO Date:	June 1, 1998
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$246.09M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.16 | 2.84%
Avg Daily Range (30 D):	$0.07 | 2.92%
Avg Daily Range (90 D):	$0.06 | 2.96%

Institutional Daily Volume
Avg Daily Volume:	.32M
Avg Daily Volume (30 D):	1.41M
Avg Daily Volume (90 D):	.95M

Trade Size
Avg Trade Size (Sh.):	230
Avg Trade Size (Sh.) (30 D):	206
Avg Trade Size (Sh.) (90 D):	203

Institutional Trades
Total Institutional Trades:	283
Avg Institutional Trade:	$1.6M
Avg Institutional Trade (30 D):	$.59M
Avg Institutional Trade (90 D):	$.59M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$5M
Avg Closing Trade (30 D):	$.58M
Avg Closing Trade (90 D):	$.58M
Avg Closing Volume:	628.06K

News

Mar 26, 2025 @ 7:00 PM [Latest] Global Fabry Disease Treatment Market Siz... Source: Custom Market Insights

Jun 12, 2024 @ 3:45 PM Pluxee to acquire Cobee, an innovative Spanish dig... Source: Pluxee N.V

Jun 12, 2024 @ 3:45 PM Pluxee signe un accord pour l’acquisition d... Source: Pluxee N.V

Jun 12, 2024 @ 3:45 PM Pluxee firma un acuerdo para adquirir Cobee, empre... Source: Pluxee N.V

Apr 22, 2024 @ 4:00 PM Declaration of transactions in own shares n 2024/0... Source: Pluxee International

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$.08	$.03
Diluted EPS	$.08	$.03
Revenue	$61.84M	$17.85M
Gross Profit	$35.58M	$9.53M
Net Income / Loss	$5.39M	$2.36M
Operating Income / Loss	$6.37M	$2.13M
Cost of Revenue	$26.26M	$8.32M
Net Cash Flow	$-13.8M
PE Ratio	37.50

Splits
Dec 20, 2019	1:10
Jan 03, 2007	1:10